Novartis – Newsemia

STAT Plus: Pharmalittle: Novartis to pay $9.7 billion for The Medicines Co.; Trump bashes Pelosi drug pricing bill

NewsemiaNovember 25, 2019

by NewsemiaNovember 25, 201900

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so-familiar routine of meetings, Skype...

Latest News

Global Ophthalmology Therapeutics Market 2019-2023 | Evolving Opportunities with ALLERGAN and Novartis AG | Technavio

NewsemiaNovember 25, 2019

by NewsemiaNovember 25, 201900

LONDON–(BUSINESS WIRE)– #HealthcareDevices–Global ophthalmology therapeutics market is poised to grow by USD 9.6 billion during 2019-2023 at a CAGR of nearly 6% during the forecast...

Latest News

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

NewsemiaNovember 25, 2019

by NewsemiaNovember 25, 201900

Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days of rumors, is a story of second acts. It represents...

Latest News

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion

NewsemiaNovember 24, 2019

by NewsemiaNovember 24, 201900

PARSIPPANY, N.J.–(BUSINESS WIRE)—- $MDCO–The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines...

Latest News

Novartis announces strategy to broaden patient reach and availability of medicines in sub-Saharan Africa

NewsemiaNovember 13, 2019

by NewsemiaNovember 13, 201900

Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa, which is home to the...

Latest News

STAT Plus: Pharmalittle: Pelosi claims trade deal shows progress on drug issues; Novartis suffers another trial setback

NewsemiaNovember 3, 2019

by NewsemiaNovember 3, 201900

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal...

Latest News

STAT Plus: Pharmalittle: FDA places hold on Novartis trial for gene therapy; FDA floats plan for combating shortages

NewsemiaOctober 30, 2019

by NewsemiaOctober 30, 201900

Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? While you ponder the...

Latest News

Novartis gene therapy brings in $160 million, beating expectations

NewsemiaOctober 22, 2019

by NewsemiaOctober 22, 201900

Zolgensma, a lifesaving treatment for infants and the world’s most expensive drug, has been used to treat 100 patients since its launch and brought in...

Latest News

STAT Plus: Novartis partners with Microsoft to use AI in drug development

NewsemiaOctober 1, 2019

by NewsemiaOctober 1, 201900

Novartis and Microsoft have inked a five-year deal to use artificial intelligence to design molecules, personalize medication dosing, and optimize the manufacturing of CAR-T cancer...

Latest News

Digital Dose Inhalers Market 2019-2023 – Evolving Opportunities With AstraZeneca Plc and Novartis AG | Technavio

NewsemiaSeptember 20, 2019

by NewsemiaSeptember 20, 201900

LONDON–(BUSINESS WIRE)– #Biotechnology–The global digital dose inhalers market size will grow by USD 989.44 million during 2019-2023. Source link...

Gastroenterology

Novartis stops distribution of Zantac

NewsemiaSeptember 19, 2019

by NewsemiaSeptember 19, 201900

Zantac manufacturer Novartis has stopped the distribution of its heartburn medication across all available markets, including the United States and Canada, Reuters reported.The halt in...

Latest News

Sanofi’s billion-dollar multiple sclerosis drug faces competitive threat from Novartis, J&J agents

NewsemiaSeptember 15, 2019

by NewsemiaSeptember 15, 201900

On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi’s Aubagio. Johnson & Johnson’s Janssen division had presented data for...

Latest News

STAT Plus: Reeling from scandal, Novartis vows to voluntarily release info on manipulated data in the future

NewsemiaSeptember 9, 2019

by NewsemiaSeptember 9, 201900

Seeking to appease angry regulators, Novartis (NVS) committed to notifying the Food and Drug Administration within five business days of learning of any “credible allegation”...

Latest News

STAT Plus: Pharmalittle: AstraZeneca stumbles in lung cancer; FDA official on Novartis data scandal says ‘we got lucky’

NewsemiaAugust 25, 2019

by NewsemiaAugust 25, 201900

Rise and shine, everyone, the middle of the week is already here. Time flies when you’re having … fill in the blank here. Meanwhile, a...

Latest News

Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal

NewsemiaAugust 19, 2019

by NewsemiaAugust 19, 201900

The Novartis scientist who was ousted by the drug maker in connection with a scandal over data manipulation broke his silence late Monday, saying through...

Latest News

STAT Plus: Pharmalittle: Novartis exec sold stock before FDA announced data scandal; FDA OKs fewer new generics this year

NewsemiaAugust 19, 2019

by NewsemiaAugust 19, 201900

Good morning, everyone, and welcome to another working week. We hope the weekend respite — or holiday break, for some — was invigorating and refreshing,...

Latest News

STAT Plus: Pharmalittle: New antibiotic approved for drug-resistant TB strain; Novartis dismissed top scientists over data scandal

NewsemiaAugust 19, 2019

by NewsemiaAugust 19, 201900

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially since the Pharmalot campus is unusually quiet. A short...

Latest News

Memo to the Novartis CEO: When in doubt, give the FDA a heads-up

NewsemiaAugust 13, 2019

by NewsemiaAugust 13, 201900

For someone who has made a point of trying to steer Novartis (NVS) away from scandal, Vas Narasimhan has committed a puzzling blunder. Last week,...

Latest News

Listen: Novartis and the no good, very bad week

NewsemiaAugust 11, 2019

by NewsemiaAugust 11, 201900

Why did Novartis keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time? We discuss...

Latest News

Senators blast Novartis over data manipulation before approval of Zolgensma

NewsemiaAugust 9, 2019

by NewsemiaAugust 9, 201900

WASHINGTON — A group of senators, including presidential hopefuls Sens. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.), blasted Novartis on Friday for failing to promptly...